Red light therapy for hair loss and thinning

Hair loss in the UK - a bigger picture than people expect

Around 8 million people in the UK are affected by hair loss at any given time. The most common form - androgenetic alopecia (AGA), or pattern hair loss - affects up to 70% of men and around 40% of women over the course of their lives. That is not a niche problem. It is one of the most prevalent conditions a GP sees, and one of the least satisfactorily treated.

The treatments available until recently were limited: minoxidil (topical, applied daily, causes shedding when stopped), finasteride (oral, prescription only, not appropriate for women of childbearing age), and hair transplant surgery for those with enough donor density to make it viable. All effective within limits. None particularly convenient. None addressing the underlying cellular biology in a way that slows the progression long-term without ongoing pharmaceutical use.

Red light therapy - more formally called low-level laser therapy (LLLT) or photobiomodulation (PBM) - has been used in clinical settings for hair loss since the early 2000s. It received FDA clearance in the United States for male pattern hair loss in 2007, and for female pattern hair loss in 2011. The evidence base has grown considerably since. The question is not whether it works - multiple trials confirm it does for the right type of hair loss. The question is who it works for, how well, and what realistic expectations look like.

How red light therapy works on hair follicles

Hair follicles are among the most metabolically active structures in the body. Growing a single strand of hair requires a significant and sustained energy output from the cells at the follicle base. Like all cells, follicles run on ATP (adenosine triphosphate) - the molecule that powers virtually every cellular function. When follicle mitochondria (the energy-generating components of cells) are running below capacity, that energy output falls, and the follicle progressively miniaturises - producing thinner, shorter, weaker hairs until it eventually stops producing at all.

Red and near-infrared light (630-850nm) is absorbed by cytochrome c oxidase, a light-sensitive enzyme inside the mitochondria of hair follicle cells. This triggers a chain of cellular responses: ATP production increases, oxidative stress in the follicle decreases, and blood circulation to the scalp improves. The follicle has more energy available - and energy is precisely what it needs to stay in its growth phase (anagen) for longer.

There are two secondary mechanisms that matter for different types of hair loss. First, red light reduces scalp inflammation - and chronic low-grade inflammation of the follicle is a significant driver of miniaturisation in pattern hair loss. Second, RNA sequencing research on human hair follicles published in 2021 (Annals of Dermatology) found that 650nm light directly modulates androgen receptor signalling (the pathway through which DHT - the hormone that causes pattern hair loss - damages follicles). This is important: it suggests red light is not just adding energy passively, but interfering with the hormonal damage pathway itself.

Pattern hair loss (androgenetic alopecia) - the strongest evidence

Androgenetic alopecia is the form with by far the strongest clinical trial evidence for red light therapy. The mechanism is well understood: the hormone DHT (dihydrotestosterone - a potent derivative of testosterone) progressively miniaturises hair follicles in genetically predisposed people. In men this typically follows the Norwood-Hamilton scale - temples, crown, then vertex. In women it tends to be more diffuse central thinning, usually without full baldness, classified on the Ludwig scale.

What the trials show

A 2013 double-blind randomised controlled trial published in Lasers in Surgery and Medicine (Lanzafame et al.) enrolled 44 men with androgenetic alopecia. Participants used a 655nm helmet device every other day for 16 weeks - 60 treatments total. Hair count in a standardised scalp area was photographed and measured by a blinded evaluator. The active treatment group showed significantly improved hair counts compared to the sham (placebo) group receiving identical-looking treatment with no therapeutic output.

A 2014 multicentre randomised controlled trial (Jimenez et al., American Journal of Clinical Dermatology) enrolled 128 men with pattern hair loss. Active treatment with a 655nm laser device versus sham device over 26 weeks produced a mean increase of 20.2 terminal hairs per cm2 in the treated group, versus 2.9 hairs per cm2 in placebo. A separate arm of the same research programme enrolled women and showed comparable results.

A 2024 systematic review and meta-analysis by Perez et al. (Dermatologic Surgery) analysed 38 studies covering 3,098 patients. For androgenetic alopecia specifically, the mean change in hair density after LLLT was significantly greater than placebo across all treatment durations - with the effect growing stronger at longer treatment periods (standardised mean difference of 1.44 at over 20 weeks, compared to 1.14 under 20 weeks). Effect sizes in this range indicate a clinically meaningful result in the research literature.

A 2025 double-blind RCT by Thomas et al. (Dermatologic Surgery) specifically tested dual-wavelength LED treatment in androgenetic alopecia and found significant improvements in hair count and density at 16 weeks, with the authors concluding the device was both safe and effective. Dual-wavelength protocols (combining red and near-infrared) are increasingly the standard in newer research.

Stress shedding and telogen effluvium

Telogen effluvium (TE) is the second most common form of hair loss. It occurs when a large proportion of follicles prematurely shift from the active growth phase (anagen) into the resting phase (telogen), resulting in diffuse shedding - often noticed as handfuls of hair in the shower, or visible thinning across the whole scalp rather than in a pattern. Common triggers include physical illness, surgery, rapid weight loss, childbirth, severe psychological stress, thyroid changes, and nutritional deficiencies.

TE is often temporary - if the trigger resolves, most people recover within 6-12 months. But it can be prolonged, particularly when the original trigger is ongoing (chronic stress, unresolved thyroid issues, ongoing nutritional deficiency), and it can coexist with underlying androgenetic alopecia in ways that accelerate that condition.

What the research shows

The evidence for red light therapy in TE is less voluminous than for AGA, but the direction is consistently positive. The 2025 University of Miami systematic review (Nestor et al., Journal of Cosmetic Dermatology) concluded that LLLT shows potential for telogen effluvium by prolonging the anagen phase and reducing shedding, noting that the mechanism - pushing follicles back into growth phase via ATP upregulation - is directly relevant to TE's pathology.

A 2024 retrospective study by Gerkowicz et al. (Annals of Agricultural and Environmental Medicine) examined LED therapy in 140 patients with post-COVID telogen effluvium - a particularly well-characterised acute TE population. Patients in the LED treatment group showed faster resolution of hair shedding and earlier regrowth compared to controls. The researchers described LED therapy as safe, well-tolerated, and a promising adjuvant option for TE, particularly for faster reduction of shedding and accelerated regrowth.

The biological rationale is strong. TE is fundamentally a problem of premature phase transition - follicles leaving anagen too early. Red light's primary documented effect on follicles is extending anagen duration. That is a direct match.

Hormonal thinning, menopause, and female hair loss

Female hair loss is significantly underrepresented in the clinical literature despite being extremely common. Around 40% of women experience notable hair thinning at some point, and for many it coincides with hormonal transitions - the perimenopause, menopause, postpartum changes, or thyroid shifts. The pattern in women is different to men: typically diffuse thinning along the central parting and crown, with the hairline usually preserved. The Ludwig classification describes it in three stages.

Hormonal hair loss in women involves the same DHT-follicle miniaturisation pathway as in men, but the sensitivity is usually lower and the interplay with oestrogen more complex. Oestrogen has a protective role on follicles - it extends anagen duration and counteracts some DHT sensitivity. When oestrogen drops during perimenopause and menopause, that protection reduces, and androgenetic alopecia can emerge or accelerate in women who had no visible hair loss in their younger years.

What the evidence shows for women

Multiple trials in the AGA evidence base enrolled both men and women and reported results for each separately. A 24-week randomised double-blind sham-controlled multicentre trial (Leavitt et al.) used a 655nm laser device in men and women with androgenetic alopecia and found significant improvements in hair density in both groups, with comparable effect sizes. Female participants in the Jimenez trial programme also showed meaningful improvements in terminal hair density over 26 weeks.

The 2025 Nestor et al. review found that LLLT improves hair density and follicular responsiveness in female androgenetic alopecia, and noted enhanced outcomes when combined with minoxidil - which is the standard topical treatment most often used in women (finasteride is not typically prescribed for women of childbearing potential). Importantly, the review found no meaningful adverse effects reported across any of the 63 included studies.

What red light therapy can and cannot do for hair

The evidence is clear enough now to be specific about the boundaries. Being clear matters because the space between legitimate benefit and overclaim is where most of the misleading marketing sits.

How to use red light therapy for hair loss

The clinical protocols are consistent enough across the trial literature to be specific. The main variables are wavelength, irradiance (light output), coverage, frequency, and duration.

Wavelengths for hair

Frequency, session length and timeline

Clinical trials showing the strongest results typically used three to five sessions per week, each lasting 15-30 minutes. The dose-response relationship in hair is well established: more frequent sessions within that range produce faster results. Consistency matters more than individual session intensity - sporadic use does not accumulate the way regular use does.

Timeline expectations are the most important thing to get right before starting. Hair growth is slow. The hair cycle runs over months, not weeks. Most trials that show meaningful results measured outcomes at 16-26 weeks - roughly four to six months of consistent use. Expect to see some change in shedding rate by 8-12 weeks. Visible density improvement typically requires four months minimum, often six. If treatment is stopped, hair loss will gradually resume - similar to stopping minoxidil. Ongoing maintenance is part of the protocol.